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Abstract
Aims/hypothesis We previously demonstrated hepatocyte
growth factor (HGF) gene therapy was able to induce re-
gression of glomerulosclerosis in diabetic nephropathy
through local reparative mechanisms. The aim of this study
was to test whether bone-marow-derived cells are also in-
volved in this HGF-induced reparative process.
Methods We have created chimeric db/db mice as a model
of diabetes that produce enhanced green fluorescent protein
(EGFP) in bone marrow cells. We performed treatment with
HGF gene therapy either alone or in combination with
granulocyte-colony stimulating factor, in order to induce
mobilisation of haematopoietic stem cells in these diabetic
and chimeric animals.
Results WefindHGFgenetherapyenhancesrenalexpression
ofstromal-cell-derivedfactor-1andissubsequentlyassociated
with an increased number of bone-marrow-derived cells get-
ting into the injured kidneys. These cells are mainly
monocyte-derived macrophages, which may contribute to
the renal tissue repair and regeneration consistently observed
inourmodel.Finally,HGFgenetherapyisassociatedwiththe
presence of a small number of Bowman’s capsule parietal
epithelial cells producing EGFP, suggesting they are fused
with bone-marrow-derived cells and are contributing to podo-
cyte repopulation.
Conclusions/interpretation Altogether, our findings provide
new evidence about the therapeutic role of HGF and open
new opportunities for inducing renal regeneration in diabetic
nephropathy.
Keywords Bonemarrowstemcells.Diabetic nephropathy.
HGFgenetherapy.Macrophages.Renalrepair
Abbreviations
BMT Bone marrow transplantation
CKD Chronic kidney disease
CTGF Connective tissue growth factor
EGFP Enhanced green fluorescent protein
G-CSF Granulocyte-colony stimulating factor
GFP Green fluorescent protein
HGF Hepatocyte growth factor
HSC Haematopoietic stem cell
PBMC Peripheral blood mononuclear cell
PEC Parietal epithelial cell
SDF-1 Stromal-cell-derived factor-1
Introduction
Chronic kidney disease (CKD) is a major health problem
worldwide [1]. CKD is a risk factor for cardiovascular
diseases and mortality. Diabetic nephropathy is the lead-
ing cause of CKD in developed countries [2]. Diabetic
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losclerosis, arteriolar hyalinosis and tubulo-interstitial fibrosis
[3]. As in other diseases evolving to renal scarring, growth
factors such as TGF-β1 and connective tissue growth factor
(CTGF) are involved in the progression of renal damage [4].
Thereareveryfewtherapiesthatinducerenalrepairinchronic
nephropathies [5]. Hepatocyte growth factor (HGF) is a
mesenchyme-derived cytokine with anti-fibrotic and regener-
ative properties in some experimental models of chronic renal
damage [6, 7]. HGF inhibition exacerbates renal fibrosis,
whereas HGF supplementation reverses progression [8–11].
WehavepreviouslystudiedtheeffectofHGFgenetherapyon
diabetic kidney disease in rats and have demonstrated HGF-
supplementation-induced regression of glomerular sclerosis
[12].The reparativeroleofHGFhas beenrobustlyrecognised
in many studies [11]. The majority of HGF-established re-
parative mechanisms are directly related to a local effect of
TGF-β1 inhibition [13], by increasing extracellular matrix
degradation [14] or by inhibiting epithelial to mesenchymal
transition [15]. However, there is a lack of information about
the potential role of bone-marrow-derived cells on the regres-
sion of CKD induced by HGF. Kollet et al [16]d e m o n s t r a t e d
that, after liver injury, HGF facilitated bone marrow haemato-
poietic stem cell (HSC) motility, CXCR4 expression and
stromal-cell-derived factor-1 (SDF-1)-mediated directional
migration of these cells to the damaged liver. More recently,
Higashiyama et al [17] studied spontaneous liver regeneration
aftercirrhosisinwild-typeandtransgenicanimalsoverexpress-
ing Hgf. Animals overexpressing Hgf healed more rapidly
because resident as well as bone-marrow-derived cells infil-
trating the liver were producing some metalloproteases that
mainly contributed to regression of liver fibrosis.
In order to study whether bone-marrow-derived cells are
involved in the reparative mechanisms of HGF on diabetic
kidney disease, we have created chimeric diabetic db/db mice.
We performed bone marrow transplantation (BMT) using
transgenicC57BL/6Jmiceproducingtheenhancedgreenfluo-
rescent protein (EGFP) as donors to db/db mouse recipients.
Methods
Animals
The experiments complied with current legislation on ani-
mal experiments in the European Union, and the principles
of laboratory animal care and were approved by our institu-
tion’s Ethics Committee for Animal Research. Female
C57BLKS mice (db/db), 8 weeks old, were purchased from
Janvier (Laval, France). Transgenic C57BL/6J mice produc-
ing EGFP were kindly provided by J. Barquinero (Unitat de
Diagnòstic i Teràpia Molecular, Centre de Transfusió i Banc
de Teixits, Barcelona, Spain).
Bone marrow transplantation
Bone marrow isolation In a sterile environment, bone
marrow cells were isolated from the femurs and tibias of
C57BL/6J EGFP
+ mice, by flushing the bones with Iscove’s
modified Dulbecco’s Medium (Invitrogen, Madrid, Spain)
supplemented with 10% (vol./vol.) FBS, penicillin/strepto-
mycin and L-glutamine. Samples were passed through a
70 μm cell strainer (BD Biosciences, Aalst, Belgium)
to eliminate debris and break up cell clumps. After wash-
ing twice, cells were resuspended in PBS and stored at
4°C.
Irradiation and bone marrow transplantation We performed
BMT from EGFP
+ C57BL/6J donor mice. Recipients were
obese mice C57BLKS (db/db) as a model of diabetes. These
animals were transplanted at 24 weeks of age, an age at
which diabetic nephropathy is already established. Re-
cipient db/db mice were lethally irradiated with a dose
o f1 0 . 5G ya n dr e c o n s t i t u t e d1hp o s ti r r a d i a t i o nw i t h
7.5×10
6 donor cells/animal by intravenous injection in the
tail vein, as previously described [18]. After BMT, trans-
planted animals were placed in cages in a sterile environment
for 10 days.
Chimerism analysis Chimerism was analysed 5 weeks after
BMT. Peripheral blood was extracted from the tail vein.
Blood was collected in Microvette CB300 with EDTA tubes
(Sarstedt, Madrid, Spain). A 50 μl blood sample was mixed
with 1 ml lysis buffer (BD Biosciences, San Jose, CA, USA)
in order to discard red cells and the mixture was then
incubated at 37°C for 3 min. Samples containing peripheral
blood mononuclear cells (PBMCs) were washed twice
(200 g, 5 min), stained with a viability marker, 7-amino-
actinomycin D (BD Biosciences, San Jose, CA, USA), in
order to distinguish living cells from dead cells, and were
finally analysed by BD FACSCanto II (BD Biosciences, San
Jose, CA, USA). Animals were considered chimeric when
the percentage of EGFP
+ cells was higher than 30% of the
total PBMCs.
Study groups
Chimericanimalsweredivided intofourtreatmentgroupsand
followed for 4 weeks: (1) db/db–BMT (n011), diabetic ani-
mals with BMT; (2) db/db+HGF (n012), diabetic animals
withBMTandtreatedbyHGF;(3)db/db+granulocyte-colony
stimulating factor (G-CSF) (n010), diabetic animals with
BMT and treated by G-CSF and (4) db/db+HGF+G-CSF
(n011), diabetic animals with BMT and treated by HGF and
G-CSF. We used db
/− (n010), non-diabetic animals, and
db/db (n010), diabetic animals, as age-matched control
groups.
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HGF gene therapy The HGF expression vector used in the
present study was constructed and optimised as previously
described by our group [19]. Two hours before HGF admin-
istration, 25 U of hyaluronidase (Sigma, Seelze, Germany)
diluted in 60 μl of NaCl was injected into the muscle in
order to improve plasmid DNA diffusion. Then, 50 μlo f
HGF (2 μg/μl) was injected into each leg. After the HGF
intramuscular injection, the area around the injection was
electroporated. The electric pulses were applied to the muscle
by pulse generator (BTX ECM830 electroporator; Gene-
tronics, San Diego, CA, USA) [19]. Six pulses of 100 ms,
each with a voltage of 25 V, were applied. This protocol was
performed twice, at days 3 and 17. Human HGF levels were
analysed by Quantikine Human HGF immunoassay (R&D
Systems, Oxford,UK)inorder toassesstheefficiencyofgene
therapy.
G-CSF administration G-CSF(Filgrastim,Amgen,Thousand
Oaks, CA, USA), 300 μgk g
−1 day
−1, was intraperitoneally
administrated for 12 days in two periods, from days 1 to 6 and
from days 15 to 20. Leucocyte counts were analysed to assess
the response to G-CSF.
Monitoring
Animals were followed from 8 to 33 weeks of age. During
this period glucose levels and body weight were measured
weekly (glucose was measured using the Glucocard G+meter
GT-1820 [Menarini, Barcelona, Spain]). BMTwas performed
when animals were 24 weeks old. Chimerism was analysed
5 weeks after BMT, and the animals were killed in week 33.
Urine and blood samples were collected in order to analyse
urinary albumin and serum creatinine concentrations at three
time points: before BMT (24 weeks of age), when chimerism
was analysed (29 weeks of age) and before the mice were
killed (33 weeks of age).
Mice were placed in metabolism cages in order to collect
24 h urine specimens before BMT (week 24), and thereafter
beforeand after therapeutic interventions (at weeks 29and 33,
respectively). Blood was obtained from the tail vein. Serum
creatinine and urine creatinine were determined by an auto-
analyser (Olympus AU400; Olympus, Hamburg, Germany).
Urine albumin excretion was determined using a specific
commerciallyavailableELISAkit(AlbuminBlueFluorescent
Assay Kit; Active Motif, La Hulpe, Brussels, Belgium).
Circulating haematopoietic stem cells
Analysis of HSCs was performed using a BD FACSCanto II
(BD Biosciences, San Jose, CA, USA). Peripheral blood
was collected at baseline and then 2 and 5 days after each
HGF administration. Whole blood was incubated with
allophycocyanin-conjugated anti-lineage (Lin) cocktail,
phycoerythrin (PE)-Cy7-conjugated anti-cKit (also known
as CD117) and PE-conjugated anti-stem cell antigen (Sca)-1
antibodies (BD Biosciences, Aalst, Belgium). Blood was
then incubated with lysis buffer in order to discard eryth-
rocytes. PBMCs were finally incubated with 7-amino-
actinomycin D for dead cell staining. PBMCs were consid-
ered HSCs when they were Lin
− cKit
+ Sca-1
+ as previously
described [20].
Optical microscopy, immunohistochemical,
immunofluorescence and confocal studies
Renal slices were fixed in 10% (vol./vol.) formalin and
embedded in paraffin. Histological cross sections of 3 μm
thickness were stained with haematoxylin and eosin, peri-
odic acid–Schiff and Masson’s trichrome for optical micros-
copy assessment. Fibronectin (1:500) and SDF-1 (1:25)
(Abcam, Madrid, Spain) were stained using the immunohis-
tochemical technique described previously [21]. Anti-
collagen IV (1:100; Millipore, Livingston, UK), anti-green
fluorescent protein (GFP; 1:500, Abcam), anti-α-smooth
muscle actin (SMA) (1:100, Sigma-Aldrich, Madrid, Spain),
anti-claudin-I (1:19, Invitrogen, Paisley, UK), anti-WT-1
(1:30, Santa Cruz Biotechnology, Heidelberg, Germany),
anti-F4/80 (1:50, LabClinics, Barcelona, Spain), anti-
galectin-3 (1:100, Abcam) and anti-mannose-receptor (1:50,
Abcam)antibodieswereanalysedusingimmunofluorescence.
Slides werestained with: collagen IVand fibronectin toassess
glomerulosclerosis; α-SMAtostainmesangialcells;claudin-I
for epithelial cells from the Bowman’s capsule; WT-1 for
podocytes; F4/80 for macrophages; CD90, CD73, CD105
for mesenchymal cells; CD34 for endothelial cells; and
galectin-3 and mannose receptor for the M2 macrophage
subpopulation.
Double immunolabelling was performed using anti-GFP
with anti-α-SMA, anti-claudin-I, anti-WT-1 or anti-F4/80
antibodies; and anti-F4/80 with anti-galectin-3 and anti-
mannose receptor. Optical microscopy, fibronectin, SDF-1
and collagen IV were evaluated (from 0 to +3) by a pathol-
ogist (A. Vidal) who was blinded to group assignment.
Macrophages and the M2 subpopulation were evaluated in
ten glomeruli for every sample in a blinded manner. Mac-
rophage counts were expressed as macrophage/glomeruli.
The percentage of M2
+ with respect to F4/80+ macrophages
was calculated (n04 per group).
Additional renal slices were embedded and frozen in
optimal cutting temperature compound. Subsequently, cross
sections of 5 μm thickness were fixed with 4% (wt/vol.)
paraformaldehyde at 4°C for 20 min and incubated with the
following primary antibodies: anti-CD90; anti-CD73; anti-
CD105; and anti-CD34 (1:50, BD Pharmingen, Aalst,
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was directly viewed with microscopy and automatically
quantified using Leica Confocal Software. Finally, confocal
studies (using a Leica TCS-SL confocal espectral micro-
scope [Mannheim, Germany]) were performed in a blinded
manner on paraffin-embedded and frozen renal tissues.
Alexa Fluor647 (far red), Alexa Fluor488 (green), Alexa
Fluor546 (red) and Alexa Fluor555 (red) were used as
secondary antibodies (Molecular Probes, Invitrogen, Madrid,
Spain). In a blinded manner, podocytes per glomerular tuft
were quantified in ten glomeruli per sample and calculated as
podocyte/total nuclei ratio. Nuclei were stained blue with
DRAQ5 and counted using Fiji Is Just ImageJ software
(http://fiji.sc).
Gene expression analysis
RNA was extracted from kidney with PureLink RNA Mini
Kit (Invitrogen, Madrid, Spain), using a Trizol reagent
(Invitrogen, Madrid, Spain) to lyse the tissues, chloroform
to separate the aqueous phase and organic phase (where the
RNA remains), and ethanol to purify the RNA. RNA purity
was analysed on a NanoDrop (NanoDrop ND-1000V3.3,
Wilmington, DE, USA) and was considered pure when the
absorbance ratio 260/280 nm was lower than 1.75. A total
amount of 1,000 ng RNA was used to perform the reverse
transcription using a High-Capacity cDNA Reverse Tran-
scriptionKit(AppliedBiosystems,Warrington,UK).Thermal
cycling conditions were 10 min at 25°C, 120 min at 37°C,
5minat85°Candfinallyheldat4°C.Tissueexpressionlevels
of HGF, TGFβ (also known as TGFB1) and CTGF were
quantified by TaqMan real-time PCR (ABI Prism 7700, Ap-
plied Biosystems) using the comparative Ct method
(Applied Biosystems).
Cytokine analysis
Serumcytokineswerequantitativelymeasured byFACSCanto
withtwo differentcytometric bead array (CBA) kits: the CBA
mouse inflammation kit (IL-6, IL-10, MCP-1, IFN-γ,T N F
and IL-12p70) and the CBA mouse Th1/Th2 cytokine kit
(IL-4, IL-5, IFN-γ and TNF), both from BD Biosciences
(San Jose, CA, USA). Data were acquired and analysed using
BD CBA software (San Jose, CA, USA). If a sample had a
cytokine concentration below the detection limit of the
assay, a value of 0 was assigned for that particular cytokine
concentration.
Statistical analyses
All data are presented as mean±SE. Group means were
compared with either the Student’s t test or ANOVA for
parametric values, or the Mann–Whitney U test or Kruskal–
Wallis test for non-parametric values. All p values were two-
tailed, and a p value of less than 0.05 was considered statisti-
cally significant. All statistical analyses were analysed using
StatView software.
Results
Bone marrow transplantation does not modify features
of diabetic nephropathy in db/db mice
As we performed the experiments in EGFP
+ chimeric mice,
we first investigated whether BMT modified diabetic ne-
phropathy in db/db mice. As shown in Table 1 and Fig. 1,
both diabetic groups (db/db and db/db–BMT) were signifi-
cantly different from the non-diabetic db
/− group for body
weight and albuminuria, as well as hyperglycaemia and
glomerulosclerosis. There were no major differences be-
tween db/db and db/db–BMT. However, body weight was
lower in the db/db–BMT mice compared with the db/db
group, as would be expected as irradiation is usually asso-
ciated with loss of body weight [22].
HGF is renoprotective in chimeric db/db mice
Baseline and post-intervention functional variables are sum-
m a r i s e di nT a b l e1. Glucose levels remained similar in
diabetic-treated and non-treated groups, suggesting that nei-
ther HGF nor G-CSF treatments have any effect on hyper-
glycaemia. Nevertheless, HGF gene therapy and/or G-CSF
administration halted progression of albuminuria. We fur-
ther assessed whether these therapies had a role in the
progression of glomerulosclerosis (Fig. 2a, b). The animals
receiving HGF either alone or in combination with G-CSF
showed significant reduction in both collagen IV and fibro-
nectin glomerular deposition. Isolated G-CSF therapy was
not associated with any significant reduction of glomerulo-
sclerosis. Accordingly, HGF gene therapy rather than G-
CSF reduced the Tgf-β/Hgf m R N Ar a t i oi nr e n a lt i s s u e
(Fig. 3).
Hematopoietic stem cell mobilisation and SDF-1 renal
production induced by HGF and G-CSF resulted
in increased numbers of EGFP
+ cells in the diabetic kidney
We analysed whether HGF induced HSC mobilisation into
peripheral blood (Fig. 4a). No mobilisation was observed
when animals received HGF (db/db–BMT+HGF). The ad-
dition of G-CSF to these animals significantly increased the
number of circulating HSCs. We found HGF supplementa-
tion was associated with enhanced SDF-1 production in
renal tissue (Fig. 4b, c). However, mobilisation of bone
marrow cells by administration of G-CSF led to an increased
2062 Diabetologia (2012) 55:2059–2068number of these cells in the kidney, as shown in Fig. 5.
Administration of HGF also led to an increase in renal
EGFP
+ fluorescence, conceivably because of its ability to
induce SDF-1 production in renal tissue. The combination
of HGF gene therapy with HSC mobilisation by G-CSF
robustly increased the amount of bone-marrow-derived
EGFP
+ cells in the diabetic kidney (Fig. 5a). We found
bone-marrow-derived cells in the renal cortex and medulla
(Fig. 5b). Some of these EGFP
+ cells were localised in
diabetic glomeruli (Fig. 5c).
Renal EGFP
+ cells are mainly macrophages
There were very few mesenchymal stem cells and all of them
were EGFP
− (data not shown). Nevertheless, the majority of
EGFP
+ cells located in the kidney expressed the macrophage
marker F4/80 (Fig. 6). However, there were also a small
number of EGFP
− macrophages. Macrophages were mainly
localised around the glomeruli and in the interstitial area.
Nearlyall ofthe F4/80
+ cells wereEPGP
+, which means these
cells were bone-marrow-derived macrophages.
HGF gene therapy reduces the inflammatory milieu
and enhances the proportion of M2 glomerular macrophages
In order to test whether HGF modifies the inflammatory
response we measured serum levels of some Th1, Th2 and
pro-inflammatory cytokines in HGF-treated groups (Table 2).
HGF alone and in combination with G-CSF significantly
reduced IL-6 and MCP-1. There was also a trend to reduce
Th1 cytokines (TNF-α, IFN-γ, IL-12p70) and to enhance
some Th2 cytokines (IL-4, IL-10), although these relation-
ships did not reach statistical significance. We evaluated the
expression of M2 markers in glomerular macrophages by
confocal microscopy (Fig. 7). In agreement with the
results shown in Fig. 5, HGF, G-CSF and the combination
of both were associated with an increased number of glomer-
ular macrophages. Nevertheless, the percentage of macro-
phages expressing the M2 markers galectin-3 and mannose
receptor was nearly double in animals treated with HGF vs
those receiving G-CSF alone (Fig. 7b).In diabeticnon-treated
mice, glomerular macrophages were seldom encountered,
although a high proportion of macrophages expressed M2
markers.
Table 1 Baseline and post-intervention variables associated with diabetic kidney disease
Characteristic db
/− db/db db/db–BMT db/db+HGF db/db+G-CSF db/db+HGF+G-CSF p
Week 29 (pre-treatment)
Body weight (g) 26.4±0.8 32.8±3 29.5±2.5 34.0±1.7* 34.4±2.3* 31.4±2.2 0.12
Glycaemia (mmol/l) 6±0.16 33±0.64* 30±1.68* 23±2.24* 27±2.55* 26±1.35* <0.0001
Albuminuria (μg/24 h) 29±4.5 535±107.7* 470.9±105.1* 456±68.2* 425±108.5* 450.4±78.8* 0.002
Diuresis (ml) 0.6±0.2 7±0.9* 6.7±1.1* 5.3±1* 5.2±1.4* 4.2±1* 0.0043
Week 33 (post-treatment)
Body weight (g) 27.6±0.9 32.4±3.3 27.1±2.4 30.1±1.5 28.4±2.2 27.8±2.3 0.56
Glycaemia (mmol/l) 6±0.21 33±0.05* 28±2.51* 25±2*
,† 26±2.85*
,† 26±1.35*
,† <0.0001
Albuminuria (μg/24 h) 23.2±6.1 851±188.8* 765.9±165.5* 499±251* 487±115.4* 303±48* 0.03
Diuresis (ml) 0.6±0.1 27±1.1* 12.5±3* 5.6±1.1 4.4±1 5.4±1.3 0.0001
*p<0.05 vs db
/−;
†p<0.05 vs db/db; ANOVA followed by post hoc Fisher’s test
Fig. 1 Glomerular sclerosis in db/db–BMT and db/db mice. Repre-
sentative Masson’s trichrome-stained glomeruli showing similar glo-
merular sclerotic lesions. Magnification ×100
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of Bowman’s capsule epithelial cells producing EGFP
and preservation of podocytes
There was no co-expression of mesangial, endothelial and
podocyte markers. Nevertheless, we found a small number
(fewer than 0.5%) of Bowman’s capsule parietal epithelial
cells (PECs) that were also EGFP
+. Interestingly, this only
happenedinmicethatreceivedHGFgenetherapyeitheralone
or in combination with G-CSF (Fig. 8a, b). Accordingly, we
found the percentage of podocytes was well preserved in
HGF-treated compared with non-treated diabetic animals
(Fig. 8c–e).
Discussion
InthepresentstudyweshowthatHGFgenetherapyenhances
renal expression of SDF-1 and is also associated with an
increasing number of bone-marrow-derived cells getting into
the injured diabetic kidney. These cells are mainly macro-
phages, which may fuse with resident epithelial cells from
the Bowman’s capsule and participate in renal repair and
regeneration.
We have created chimeric diabetic db/db mice by BMT
with bone marrow from donor transgenic EGFP
+ mice.
Thus, we obtained a diabetic mouse model with easily
identifiable bone-marrow-derived cells in blood and periph-
eral tissues. The wild-type C57BL/6J mice express leptin
receptor and may have distinct properties from their db/db
counterparts. Despite bone marrow EGFP
+ cells came from
the wild type, we proved BMT was not associated with any
significant modification of diabetic nephropathy, as there
were no differences between db/db and db/db–EGFP
+ chi-
meric mice regarding hyperglycaemia, body weight or albu-
minuria. We were also able to reproduce previous findings
from our group concerning the functional and histological
Fig. 2 Effect of HGF gene therapy on diabetic kidney disease.
a Collagen IV immunofluorescence (×630). Only HGF gene therapy
(either alone or in combination with G-CSF) was associated with a
significant decrease in collagen IV. b Fibronectin immunohistochem-
istry (×630). Groups treated with HGF therapy (db/db+HGF and db/db
+HGF+G-CSF) showed decreased fibronectin accumulation. c Histo-
gram summarising the mean values of collagen IVand fibronectin from
each group. Black bars, collagen IV; white bars, fibronectin *p<0.05
vs db/db, db/db–BMTand db/db+G-CSF;
†p<0.05 vs db/db+HGF and
db/db+HGF+G-CSF (Kruskal–Wallis and Mann–Whitney U tests)
Fig. 3 Effect of HGFgenetherapyonTGFβ1/HGFratioandCTGFgene
expression in renal tissue. Mean values of TGFβ/HGF ratio and CTGF.
Black bars, TGFβ/HGF; white bars, CTGF.* p<0.05 vs db/db+db/db–
BMT and db/db+G-CSF;
†p<0.05 vs db/db+HGF and db/db+HGF+
G-CSF; ***p<0.05vsdb
/−, db/db+G-CSF, db/db+HGF and db/db+HGF
+G-CSF (Kruskal–Wallis and Mann–Whitney U test)
2064 Diabetologia (2012) 55:2059–2068benefits of HGF gene therapy on diabetic nephropathy in
this model. Thereafter, in this work we have investigated
whether some bone-marrow-derived cells are in some way
involved in HGF-mediated renal repair.
Fig. 4 HSC mobilisation and
SDF-1 renal expression.
a Peripheral blood HSC mobi-
lisation. Only the group
receiving G-CSF had increased
circulating HSC, which was
maximal at days 8 and 22
(2 days after each G-CSF
injection). HGF had no effect
on HSC mobilisation.
Diamonds, db/db–BMT;
squares, db/db+HGF; triangles,
db/db+HGF+G-CSF. b SDF-1
renal staining: db/db–BMT;
db/db+G-CSF; db/db+HGF+G-
CSF; and db/db+HGF. Animals
treated with HGF displayed
higher production of SDF-1
in comparison with those
without HGF treatment.
c Graph illustrating the mean
values of SDF-1 production
in different treatment groups.
*p<0.05 vs db/db+HGF and
db/db–BMT+HGF+G-CSF
(Mann–Whitney U test)
Fig. 5 Evaluation of renal
EGFP
+ cells. a Mean values of
automatic EGFP quantification
in renal tissue. *p<0.02 vs
db/db+G-CSF and db/db+HGF;
**p<0.01 vs db/db–BMT,
db/db+G-CSF and db/db+HGF
(Mann–Whitney U test).
b Representative sample of
renal tissue from db/db+HGF+
G-CSF group (×40) showing
cortical (arrowhead) as well as
medullar (arrow) EGFP
+ cells.
c Glomerular detail (×630)
using CD34 staining (red) in
order to identify endothelial
cells. The asterisk shows
a glomerular extravascular
EGFP
+ cell and the arrowhead
shows a circulating EGFP
+ cell
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ence of bone-marrow-derived cells in the kidney, especially
surrounding the glomeruli, by different and unconnected
mechanisms. We observed that G-CSF consistently induced
HSC mobilisation in peripheral blood, whereas HGF had no
effect on HSC mobilisation. Nevertheless, HGF gene therapy
enhanced SDF-1 production in renal tissue, which is a major
ligand for the C-X-C chemokine receptor 4 (CXCR4) mole-
cule expressed on HSCs [23]. Enhanced SDF-1 in renal tissue
has been reported to induce homing of CXCR4
+ cells to the
kidney after ischaemic injury [24]. Accordingly, HGF en-
hancedrenal SDF-1and led toanincreased numberofEGFP
+
cells getting into the kidney, despite the lack of induced HSC
mobilisation. The combination of HGF gene therapy with
HSC mobilisation by G-CSF increased the amount of bone-
marrow-derived EGFP
+ cells in the diabetic kidney since G-
CSF induced their mobilisation and HGF induced their re-
cruitment.Thecells located aroundthe glomeruli were mainly
macrophages. In kidney disease, it has been suggested that
monocyte-derived macrophages infiltrating the kidney cause
injury and fibrosis in renal tissue [25], but can also facilitate
kidney repair and regeneration, depending on the renal milieu
[26]. Despite finding similar amounts of macrophages in
diabetic kidneys from mice treated with HGF or G-GSF, we
observed consistent histological benefit only in those receiv-
ing HGF gene therapy. The concomitant administration of G-
CSF in HGF-treated animals did not provide any additional
histological improvement. We have previously described how
HGF inhibits pro-inflammatory cytokine expression via inhi-
bition of nuclear factor κBs i g n a l l i n g[ 26]. In agreement, we
foundHGFgenetherapyreducedpro-inflammatorycytokines
and was associated with a relatively high proportion of repar-
ative M2 macrophages in glomeruli. Therefore, our findings
suggest HGF gene therapy may induce a renal microenviron-
ment that might promote macrophage-mediated renal tissue
repair and regeneration.
We tested whether there were any differentiated glomer-
ular cells co-expressing EGFP. There was no co-expression
regarding mesangial, endothelial and podocyte markers.
Nevertheless, we found a small number of Bowman’s cap-
sule PECs that were also EGFP
+. Interestingly, this only
happened in mice that received HGF gene therapy. These
highly specialised cells, which cover the glomerular capil-
lary tuft, are crucial for podocyte repair after injury [27].
Accordingly, we found the percentage of podocytes was
well preserved in HGF-treated compared with non-treated
diabetic animals. It has been suggested that some of these
PECs are actually renal stem cells that could migrate along
the Bowman’s capsule and transition to the tuft to areas of
injury and differentiate into podocytes [28]. Sagrinati et al
[28] demonstrated that PECs derive from a resident renal
population during kidney development rather than from the
bone marrow. Our data suggest these PECs expressing
EGFP derive from cell fusion. First, we found extensive
macrophage infiltrates around the capsule. Second, macro-
Fig. 6 Renal EGFP
+ cells are mainly macrophages. The arrows show
macrophages stained with F4/80 (in red), which co-express EGFP (in
green) becoming yellow and therefore suggesting a bone marrow
origin. Arrowheads show EGFP
+ cells (in green). Asterisks show some
macrophages stained with F4/80 (in red) that do not co-express EGFP
(×630)
Table 2 Serum levels of Th1, Th2 and pro-inflammatory cytokines in HGF-treated animals
Group TNF-α IFN-γ IL-12p70 IL-5 IL-4 IL-10 IL-6 MCP-1
db/db–BMT 6.5±1.6* 0.6±0.3 20±10
† 0.5±0.2 0.1±0.0 1.1±0.6 3.9±1.0
‡ 29±5.4
†
db
/− 3.4±0.7 0.4±0.3 2.1±2.0 0.2±0.1 0.4±0.3 2.0±0.7 0.4±0.2 17±2.2
db/db+HGF 2.9±0.2 0.2±0.1 6.1±2.2 0.3±0.3 0.7±0.5 3.2±1.0 1.0±0.4 16±1.9
db/db+HGF+G-CSF 1.5±0.2 0.1±0.1 6.2±3.1 0.6±0.4 0.7±0.6 2.5±1.0 0.8±0.3 16±2.0
p value 0.08 0.5 0.1 0.5 0.5 0.3 0.01 0.09
*p<0.05 db/db–BMT vs db/db+HGF+GSF;
†p<0.05 db/db–BMT vs db/–;
‡p<0.05 db/db–BMT vs db/–, db/db+HGF and db/db+HGF+GSF
(Kruskal–Wallis and Mann–Whitney U tests)
2066 Diabetologia (2012) 55:2059–2068phages have the ability to undergo cell–cell fusion with
themselves or other cell types as renal resident cells, partic-
ularly in response to inflammatory stimuli [29]. Therefore,
our data suggest HGF attracts bone-marrow-derived cells
around the renal capsule, and these can fuse with PECs and
probably help repair. Altogether, our findings add new
knowledge and open new opportunities for inducing renal
regeneration in diabetic nephropathy.
Fig. 7 Evaluation of
glomerular macrophages
expressing M2 markers.
a Macrophages are stained
with F4/80 (in red) and nuclear
M2 marker galectin-3 (green),
or transmembrane M2 marker
mannose receptor (green).
Co-staining of both macro-
phages and M2 markers shows
as yellow (arrows) (×630).
b Number of macrophages per
glomeruli. HGF gene therapy
increased the presence of
glomerular macrophages
(*p00.05, db/db–BMT vs
db/db–HGF), the majority of
them (60.0%) expressing M2
markers. Each bar represents
the mean number of macro-
phages F4/80
+ per glomeruli;
the black shading in the bars
indicates the percentage of
the total macrophages that
are M2 macrophages
Fig. 8 HGF is associated with some parietal glomerular epithelial cells
expressing EGFP and higher podocyte number. a Only mice receiving
HGF gene therapy show glomerular parietal epithelial cells that ex-
press EGFP. Arrows in merged column are pointing at cells co-
expressing claudin-I (red) and EGFP (green). b Amplified parietal
epithelial cells expressing EGFP. Nuclear podocyte staining with
WT-1 (in red) in HGF-treated (c)a n dHGF-non-treated mice (d).
Nuclei are stained in blue with DRAQ5. Pink colour is the result of
merged red (WT-1) and blue (DRAQ5). e Histogram showing the
percentage of podocytes in HGF-treated and HGF-non-treated (‘non-
treated’) animals (*p00.002, Student’s t test)
Diabetologia (2012) 55:2059–2068 2067Acknowledgments We thank B. Torrejón (Scientific and Technical
Services, UB, Barcelona, Spain) for help with confocal microscopy;
M.L.Angelotti(Laboratorio interdipartimentale di NefrologiaCellulare e
Molecolare, Università degli studi di Firenze, Florence, Italy) and C.
VarelaandM.C.Díaz(NephrologyLaboratory,DepartamentdeCiències
Clíniques, IDIBELL, Barcelona, Spain) for technical help; J. Barquinero
(UnitatdeDiagnòsticiTeràpiaMolecular,CentredeTransfusióiBancde
Teixits, Barcelona, Spain) for kindly providing the EGFP transgenic
mice; and C. Gutierrez (Oncology and Radiotherapy, ICO, Barcelona,
Spain) for helping us to implement the irradiation procedure.
Funding This study was funded by Ministerio Ciencia e Innovación-
ISCIII (PI061073, PS09/01630) grants, by a European Union grant
(SysKid project, Framework Programme 7 [FP7]) and by ISCIII-
RETIC REDinREN/RD06/0016 grant.
Contribution statement All authors participated in the conception
and design, or analysis and interpretation of the data, contributed to
drafting and revising the manuscript, and gave final approval of the
version to be published. JMC obtained funding, supervised the study,
and wrote and reviewed/edited the manuscript.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Bommer J (2002) Prevalence and socio-economic aspects of
chronic kidney disease. Nephrol Dial Transplant 17(Suppl 11):8–
12
2. Remuzzi G, Schieppati A, Ruggenenti P (2002) Clinical practice.
Nephropathy in patients with type 2 diabetes. N Engl J Med
346:1145–1151
3. Najafian B, Alpers CE, Fogo AB (2011) Pathology of human
diabetic nephropathy. Contrib Nephrol 170:36–47
4. Cooper ME (1998) Pathogenesis, prevention, and treatment of
diabetic nephropathy. Lancet 352:213–219
5. Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of pro-
gression and regression of renal lesions of chronic nephropathies
and diabetes. J Clin Invest 116:288–296
6. Tashiro K, Hagiya M, Nishizawa T et al (1990) Deduced primary
structure of rat hepatocyte growth factor and expression of the
mRNA in rat tissues. Proc Natl Acad Sci U S A 87:3200–3204
7. Liu Y (2002) Hepatocyte growth factor and the kidney. Curr Opin
Nephrol Hypertens 11:23–30
8. Matsumoto K, Mizuno S, Nakamura T (2000) Hepatocyte growth
factor in renal regeneration, renal disease and potential therapeutics.
Curr Opin Nephrol Hypertens 9:395–402
9. Matsumoto K, Nakamura T (2001) Hepatocyte growth factor:
renotropic role and potential therapeutics for renal diseases. Kidney
Int 59:2023–2038
10. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y,
Okamoto M, Nakamura T (1998) Hepatocyte growth factor prevents
renal fibrosis and dysfunction in a mouse model of chronic renal
disease. J Clin Invest 101:1827–1834
11. Liu Y, Rajur K, Tolbert E, Dworkin LD (2000) Endogenous
hepatocyte growth factor ameliorates chronic renal injury by acti-
vating matrix degradation pathways. Kidney Int 58:2028–2043
12. Cruzado JM, Lloberas N, Torras J et al (2004) Regression of
advanced diabetic nephropathy by hepatocyte growth factor gene
therapy in rats. Diabetes 53:1119–1127
13. Dai C, Liu Y (2004) Hepatocyte growth factor antagonizes the
profibrotic action of TGF-beta1 in mesangial cells by stabilizing
Smad transcriptional corepressor TGIF. J Am Soc Nephrol 15:1402–
1412
14. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD (2003)
Hepatocyte growth factor modulates matrix metalloproteinases and
plasminogen activator/plasmin proteolytic pathways in progressive
renal interstitial fibrosis. J Am Soc Nephrol 14:3047–3060
15. Yang J, Dai C, Liu Y (2005) A novel mechanism by which
hepatocyte growth factor blocks tubular epithelial to mesenchymal
transition. J Am Soc Nephrol 16:68–78
16. Kollet O, Shivtiel S, Chen YQ et al (2003) HGF, SDF-1, and
MMP-9 are involved in stress-induced human CD34+ stem cell
recruitment to the liver. J Clin Invest 112:160–169
17. Higashiyama R, Inagaki Y, Hong YY et al (2007) Bone marrow-
derived cells express matrix metalloproteinases and contribute to
regression of liver fibrosis in mice. Hepatology 45:213–222
18. Flaquer M, Franquesa M, Barquinero J et al (2009) Bone marrow
transplantation induces normoglycemia in a type 2 diabetes mellitus
murine model. Transplant Proc 41:2282–2285
19. Franquesa M, Alperovich G, Herrero-Fresneda I et al (2005) Direct
electrotransfer of hHGF gene into kidney ameliorates ischemic
acute renal failure. Gene Ther 12:1551–1558
20. Weissman IL, Shizuru JA (2008) The origins of the identification
and isolation of hematopoietic stem cells, and their capability to
induce donor-specific transplantation tolerance and treat autoim-
mune diseases. Blood 112:3543–3553
21. Herrero-Fresneda I, Torras J, Cruzado JM et al (2003) Do alloreac-
tivity andprolongedcold ischemiacausedifferentelementary lesions
in chronic allograft nephropathy? Am J Pathol 162:127–137
22. Ablamunits V, Weisberg SP, Lemieux JE, Combs TP, Klebanov S
(2007) Reduced adiposity in ob/ob mice following total body
irradiation and bone marrow transplantation. Obesity (Silver
Spring) 15:1419–1429
23. Brenner S, Whiting-Theobald N, Kawai T et al (2004) CXCR4-
transgene expression significantly improves marrow engraftment
of cultured hematopoietic stem cells. Stem Cells 22:1128–1133
24. Togel F, Isaac J, Hu Z, Weiss K, Westenfelder C (2005) Renal
SDF-1 signals mobilization and homing of CXCR4-positive cells
to the kidney after ischemic injury. Kidney Int 67:1772–1784
25. Duffield JS (2010) Macrophages and immunologic inflammation
of the kidney. Semin Nephrol 30:234–254
26. Duffield JS (2011) Macrophages in kidney repair and regeneration.
J Am Soc Nephrol 22:199–201
27. Fogo AB (2011) The targeted podocyte. J Clin Invest 121:2142–
2145
28. Sagrinati C, Netti GS, Mazzinghi B et al (2006) Isolation and
characterization of multipotent progenitor cells from the Bowman’s
capsule of adult human kidneys. J Am Soc Nephrol 17:2443–
2456
29. Ricardo SD, van Goor H, Eddy AA (2008) Macrophage diversity
in renal injury and repair. J Clin Invest 118:3522–3530
2068 Diabetologia (2012) 55:2059–2068